Cure8 research brief
The study could create a human-derived lab model to better understand and treat colitis caused by cancer immunotherapy, and to evaluate IBD drugs for that purpose without compromising tumor control.
Researchers studying immune-related adverse events, clinicians treating irColitis or IBD, and patients or caregivers interested in ICI-related gut toxicity or repurposing IBD therapies.
The investigators will use air–liquid interface (ALI) colon organoids derived from healthy donors and patients with immune-related colitis (irColitis) to see if ICI exposure activates tissue-resident CD8 T cell programs observed in patient tissue.
They plan to test clinically used immunosuppressive biologics (listed in the project as anti-TNF and anti-IL12/23 or anti-IL23 agents) in the organoid system to evaluate effects on immune activation without affecting tumor immunity.
This is a funded research project description, not a clinical trial result; it describes research aims and planned experiments rather than findings.
Project-record (NIH Reporter) describing funded research aims and methods. This is not a peer-reviewed paper or trial result; it outlines planned laboratory experiments using patient-derived organoids to model irColitis and test therapeutics.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...
Researchers and clinicians studying Crohn’s disease want to understand whether distinct patient subgroups exist that could affect outcomes or responses. Identifying subpopulations can guide future research into...
